 | Samir K BallasShow email addressCardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA, USA | Cardeza Foundation for Hematologic Research, Department of Medicine, Sidney ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
Samir K Ballas:Expert Impact
Concepts for whichSamir K Ballashas direct influence:Sickle cell disease,Sickle cell,Sickle cell anemia,Cell disease,Iron overload,Cell anemia,Dental complications,Acute chest syndrome.
Samir K Ballas:KOL impact
Concepts related to the work of other authors for whichfor which Samir K Ballas has influence:Sickle cell disease,Acute chest syndrome,Patients scd,Cell anemia,Fetal hemoglobin,Iron overload,Pulmonary hypertension.
KOL Resume for Samir K Ballas
| Year | |
|---|---|
| 2021 | Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA, USA |
| 2020 | Cardeza Foundation for Hematologic Research, Department of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, 1020 Locust Street, Philadelphia, PA, USA Instituto de Hematologia Arthur de Siqueira Cavalcanti (HEMORIO), Rio de Janeiro, RJ, Brazil |
| 2019 | Thomas Jefferson University, Philadelphia, PA, United States. |
| 2018 | Correspondence to: Cardeza Foundation for Hematologic Research, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, USA Department of Medicine, Cardeza Foundation for Hematologic Research, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania |
| 2017 | THOMAS JEFFERSON UNIVERSITY. Cardeza Foundation for Hematologic Research, Department of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania. |
| 2016 | Cardeza Foundation for Hematologic Research, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA. Email: a Department of Hematology , Clinical Hematology Division, Instituto de Hematologia Arthur de Siqueira Cavalcanti (HEMORIO) , Rio de Janeiro , RJ , Brazil. |
| 2015 | Instituto de Hematologia Arthur de Siqueira Cavalcanti—HEMORIO Clinical Hematology Division Rio de Janeiro Rio de Janeiro Brazil Thomas Jefferson University Philadelphia Cardeza Foundation for Hematological Research Jefferson Medical College Philadelphia PA USA |
| 2014 | Cardeza Foundation for Hematologic Research, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA. |
| 2013 | From the Cardeza Foundation for Hematologic Research, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania Thomas Jefferson University Cardeza Foundation, Department of Medicine, Jefferson Medical College Philadelphia Pennsylvannia |
| 2012 | Cardeza Foundation and Department of Medicine, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA 19107, USA Department of Medicine, Jefferson Medical College, Philadelphia, Pa Thomas Jefferson University, Philadelphia, PA |
| 2011 | Jefferson School of Population Health, Thomas Jefferson University, 1015 Walnut St, Suite 115, 19107, Philadelphia, PA, USA Clinical Professor of Anesthesiology, Professor of Medical Humanities and Bioethics, University of Missouri–Kansas City School of Medicine, Kansas City, Missouri |
| 2010 | Cardeza Foundation for Hematologic Research, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA. Medicine, Thomas Jefferson University, Philadelphia, PA, USA |
| 2009 | Cardeza Foundation, Jefferson Medical College, 1015 Walnut Street, Philadelphia, PA 19107 Medicine, Jefferson Medical College, Philadelphia, PA, USA, Virginia Commonwealth University, Internal Medicine – Division of Quality Health Care, 1200 E. Broad St. Richmond, VA 23298, USA |
| 2008 | From the Departments of Hematology and Gastroenterology, The Children's Hospital & Research Center, and Children's Hospital Oakland Research Institute, Oakland, California; the Departments of Hematology, Cincinnati Children's Hospital and University of Cincinnati, Cincinnati, Ohio; Thomas Jefferson University, Philadelphia, Pennsylvania; the Department of Pediatrics, Division of Hematology, Johns Hopkins University School of Medicine, Baltimore, Maryland; the University of Alabama, Birmingham, Alabama; the Medical College of Georgia, Augusta, Georgia; Baylor College of Medicine, Houston, Texas; Toronto General Hospital, Toronto, Ontario, Canada; and the University College of London, London, UK. Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA |
| 2007 | Samir K. Ballas, MD, Cardeza Foundation, 1015 Walnut Street, Philadelphia PA 19107; phone:215-955-8485; fax 215-923-7859; samir.ballas{at}mail.tju.edu ; Samir K. Ballas, MD, Cardeza Foundation, 1015 Walnut Street, Philadelphia PA 19107; phone:215-955-8485; fax 215-923-7859; samir.ballas{at}mail.tju.edu Correspondence to: Department of Medicine, Cardeza Foundation for Hematologic Research, Philadelphia, USA |
| 2006 | Department of Medicine, Jefferson Medical College; Thomas Jefferson University; Philadelphia, Pennsylvania Cardeza Foundation, 1015 Walnut Street, Philadelphia, PA 19107 |
| 2005 | American Univ of Beirut Medical Center, Beuirut Cardeza Foundation for Hematologic Research, 1015 Walnut Street, Philadelphia, PA 19107, USA Duke Univ Medical Ctr., Durham, NC |
| Concept | World rank |
|---|---|
| society apheresis scd | #1 |
| features rbc | #1 |
| voxelotor fda | #1 |
| adult life pain | #1 |
| phase senicapoc | #1 |
| usa scd | #1 |
| crises chronic | #1 |
| blood hbno formation | #1 |
| healthy volunteers pentoxifylline | #1 |
| brazilian emergency department | #1 |
| human counterpart bands | #1 |
| newly synthesized βc | #1 |
| serum ferritin sat | #1 |
| g3pd human cells | #1 |
| drugs sickle | #1 |
| α hbf | #1 |
| crisis acute | #1 |
| reduction painful | #1 |
| undiagnosed sbetaothalassemia | #1 |
| nonnhydroxy | #1 |
| scd pain crises | #1 |
| comorbidities scd | #1 |
| produced definitions | #1 |
| alpha 2locus | #1 |
| overload organ | #1 |
| sickle cells patients | #1 |
| human cells 60 | #1 |
| albumin excretion captopril | #1 |
| deformability scd | #1 |
| rehydrate | #1 |
| thalassaemia hydroxyurea | #1 |
| 6 patients eegs | #1 |
| female globins hemoglobin | #1 |
| higher aggregates strength | #1 |
| phosphate increases studies | #1 |
| βs arab globins | #1 |
| deformability deoxygenated | #1 |
| pharmacogenomics metabolism | #1 |
| laserbackscattered techniques | #1 |
| adult patients scd | #1 |
| perennial wild plant | #1 |
| ß data | #1 |
| scd medicaid dfo | #1 |
| trials erythrocyte | #1 |
| ace inhibitors microalbuminuria | #1 |
| treatment oral complications | #1 |
| epilepsy sickle | #1 |
| purified poloxamer | #1 |
| thalassemia hbf | #1 |
| scd opioid anemia | #1 |
| Sign-in to see all concepts, it's free! | |
Prominent publications by Samir K Ballas
Angiotensin‐converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease
[ PUBLICATION ]
BACKGROUND: Sickle cell disease is a group of disorders characterized by deformation of erythrocytes. Renal damage is a frequent complication in sickle cell disease as a result of long-standing anemia and disturbed circulation through the renal medullary capillaries. Due to the improvement in life expectancy of people with sickle cell disease, there has been a corresponding significant increase in the incidence of renal complications. Microalbuminuria and proteinuria are noted to be a ...
| Known for Sickle Cell Disease | Proteinuria Microalbuminuria | Ace Inhibitors | Months Captopril | Converting Enzyme |
Angiotensin‐converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease
[ PUBLICATION ]
BACKGROUND: Sickle cell disease is a group of disorders characterized by deformation of erythrocytes. Renal damage is a frequent complication in sickle cell disease as a result of long-standing anemia and disturbed circulation through the renal medullary capillaries. Due to the improvement in life expectancy of people with sickle cell disease, there has been a corresponding significant increase in the incidence of renal complications. Microalbuminuria and proteinuria are noted to be a ...
| Known for Sickle Cell Disease | Proteinuria People | Ace Inhibitors | Months Captopril | Converting Enzyme |
BACKGROUND: Sickle cell disease is an inherited disorder of hemoglobin, resulting in abnormal red blood cells. These are rigid and may block blood vessels leading to acute painful crises and other complications. Recent research has focused on therapies to rehydrate the sickled cells by reducing the loss of water and ions from them. Little is known about the effectiveness and safety of such drugs.
OBJECTIVES: To assess the relative risks and benefits of drugs to rehydrate sickled red ...
| Known for Blood Cell | Painful Crises | Topic Clinical Trials | Phase Iii | Placebo Dose Senicapoc |
Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of Treatment
[ PUBLICATION ]
CONTEXT: Hydroxyurea increases levels of fetal hemoglobin (HbF) and decreases morbidity from vaso-occlusive complications in patients with sickle cell anemia (SCA). High HbF levels reduce morbidity and mortality.
OBJECTIVE: To determine whether hydroxyurea attenuates mortality in patients with SCA.
DESIGN: Long-term observational follow-up study of mortality in patients with SCA who originally participated in the randomized, double-blind, placebo-controlled Multicenter Study of ...
| Known for Patients Hydroxyurea | Sickle Cell | Hbf Levels | 9 Years | Acute Chest Syndrome |
BACKGROUND: Sickle cell disease is the most common single gene disorder and the commonest haemoglobinopathy found with high prevalence in many populations across the world. Management of dental complications in people with sickle cell disease requires special consideration for three main reasons. Firstly, dental and oral tissues are affected by the blood disorder resulting in several oro-facial abnormalities. Secondly, living with a haemoglobinopathy and coping with its associated ...
| Known for Dental Complications | Sickle Cell Disease | Oral Health Treatment | Special Individuals | Randomised Controlled Studies |
BACKGROUND: People affected with sickle cell disease are at high risk of infection from Haemophilus influenzae type b. Before the implementation of Haemophilus influenzae type b conjugate vaccination in high-income countries, this was responsible for a high mortality rate in children under five years of age. In African countries, where coverage of this vaccination is still extremely low, Haemophilus influenzae type b remains one of the most common cause of bacteraemias in children with ...
| Known for Sickle Cell Disease | Conjugate Haemophilus | Influenzae Type | Children Adults | African Countries |
BACKGROUND: Sickle cell disease is an inherited disorder of hemoglobin, resulting in abnormal red blood cells. These are rigid and may block blood vessels leading to acute painful crises and other complications. Recent research has focused on therapies to rehydrate the sickled cells by reducing the loss of water and ions from them. Little is known about the effectiveness and safety of such drugs.
OBJECTIVES: To assess the relative risks and benefits of drugs to rehydrate sickled red ...
| Known for Blood Cell | Painful Crises | Placebo Dose Senicapoc | Study Effectiveness | Alternative Treatment |
Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members
[ PUBLICATION ]
IMPORTANCE: Sickle cell disease (SCD) is a life-threatening genetic disorder affecting nearly 100,000 individuals in the United States and is associated with many acute and chronic complications requiring immediate medical attention. Two disease-modifying therapies, hydroxyurea and long-term blood transfusions, are available but underused.
OBJECTIVE: To support and expand the number of health professionals able and willing to provide care for persons with SCD.
EVIDENCE REVIEW: Databases ...
| Known for Sickle Cell | Opioid Anemia | Adults Scd | Treatment Hydroxyurea | Vasoocclusive Crisis |
N-Terminal Pro-Brain Natriuretic Peptide Levels and Risk of Death in Sickle Cell Disease
[ PUBLICATION ]
CONTEXT: Thirty percent of patients with sickle cell disease (SCD) develop pulmonary hypertension, a major risk factor for death in this population. A validated blood biomarker of pulmonary hypertension in SCD could provide important prognostic and diagnostic information and allow the exploration of the prevalence of pulmonary hypertension in participants in the 1996 Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH) Patients' Follow-up Study. Levels of N-terminal pro-brain ...
| Known for Pulmonary Hypertension | Risk Death | Cell Disease | Natriuretic Peptide | Patients Scd |
BACKGROUND: The acute chest syndrome is the leading cause of death among patients with sickle cell disease. Since its cause is largely unknown, therapy is supportive. Pilot studies with improved diagnostic techniques suggest that infection and fat embolism are underdiagnosed in patients with the syndrome.
METHODS: In a 30-center study, we analyzed 671 episodes of the acute chest syndrome in 538 patients with sickle cell disease to determine the cause, outcome, and response to therapy. We ...
| Known for Acute Chest Syndrome | Sickle Cell Disease | Fat Embolism | Respiratory Failure | Mechanical Ventilation |
Hydroxyurea and Sickle Cell Anemia Clinical Utility of a Myelosuppressive “Switching” Agent
[ PUBLICATION ]
Painful crises in patients with sickle cell anemia are caused by vaso-occlusion and infarction. Occlusion of blood vessels depends on (at least) their diameter, the deformability of red cells, and the adhesion of blood cells to endothelium. Deoxygenated sickle cells are rigid because they contain linear polymers of hemoglobin S (Hb S); polymerization is highly concentration dependent, and dilution of Hb S by a nonsickling hemoglobin such as fetal hemoglobin (Hb F) would be expected to ...
| Known for Cell Anemia | Fetal Hemoglobin Hb | Painful Crises | Patients Sickle | 3 Months |
A natural history study was conducted in 142 Thalassemic (Thal), 199 transfused Sickle Cell Disease (Tx-SCD, n = 199), and 64 non-Tx-SCD subjects to describe the frequency of iron-related morbidity and mortality. Subjects recruited from 31 centers in the US, Canada or the UK were similar with respect to age (overall: 25 +/- 11 years, mean +/- SD) and gender (52% female). We found that Tx-SCD subjects were hospitalized more frequently compared with Thal or non-Tx-SCD (P < 0.001). Among ...
| Known for Iron Overload | Sickle Cell | Thal Txscd | Transfused Subjects | Serum Ferritin |
Treatment of Systemic Sclerosis With Extracorporeal Photochemotherapy: Results of a Multicenter Trial
[ PUBLICATION ]
Background and Design.— In a pilot study of extracorporeal photochemotherapy, two patients with systemic sclerosis who received this therapy experienced significant clinical improvement. These results prompted the development of a multicenter trial to examine the benefit of extracorporeal photochemotherapy in the treatment of systemic sclerosis. Seventy-nine patients with systemic sclerosis of recent onset (mean symptom duration, 1.83 years) and progressive skin involvement during the ...
| Known for Systemic Sclerosis | Extracorporeal Photochemotherapy | 6 Months | Patients Therapy | Clinical Improvement |
